9-(Arenethenyl)purines as Dual Src/Abl Kinase Inhibitors Targeting the Inactive Conformation: Design, Synthesis, and Biological Evaluation

Citations Over TimeTop 10% of 2009 papers

Abstract

A novel series of potent dual Src/Abl kinase inhibitors based on a 9-(arenethenyl)purine core has been identified. Unlike traditional dual Src/Abl inhibitors targeting the active enzyme conformation, these inhibitors bind to the inactive, DFG-out conformation of both kinases. Extensive SAR studies led to the discovery of potent and orally bioavailable inhibitors, some of which demonstrated in vivo efficacy. Once-daily oral administration of inhibitor 9i (AP24226) significantly prolonged the survival of mice injected intravenously with wild type Bcr-Abl expressing Ba/F3 cells at a dose of 10 mg/kg. In a separate model, oral administration of 9i to mice bearing subcutaneous xenografts of Src Y527F expressing NIH 3T3 cells elicited dose-dependent tumor shrinkage with complete tumor regression observed at the highest dose. Notably, several inhibitors (e.g., 14a, AP24163) exhibited modest cellular potency (IC50 = 300-400 nM) against the Bcr-Abl mutant T315I, a variant resistant to all currently marketed therapies for chronic myeloid leukemia.

Related Papers

• → Ex vivo assay to determine the cyclooxygenase selectivity of non‐steroidal anti‐inflammatory drugs(1999)87 cited
• → Antagonism of in vivo and ex vivo response to endotoxin by E5564, a synthetic lipid A analogue(2002)70 cited
• → Antagonism of <I>in vivo</I> and <I>ex vivo</I> response to endotoxin by E5564, a synthetic lipid A analogue(2002)78 cited
• → Evaluation of anti-platelet and anti-thrombotic effects of cilostazol with PFA-100® and Multiplate® whole blood aggregometer in vitro, ex vivo and FeCl3-induced thrombosis models in vivo(2011)18 cited
• Effects of droxicam on in vivo prostaglandin synthesis and ex vivo platelet aggregation.(1987)